InMed Pharmaceuticals Inc.INMNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -10.36% | +7.59% | +38.51% | -11.43% | +1.23% |
| Gross Profit Growth | +42.19% | -39.33% | +68.53% | -18.29% | -92.21% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +77.22% | +128.02% | +348.97% | -99.36% | -99.44% |
| Weighted Average Shares Diluted Growth | +77.22% | +128.02% | +348.97% | -99.36% | -99.44% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -23.60% | +85.86% | +31.32% | +23.99% | -33.51% |
| Inventory Growth | +60.72% | -28.45% | -23.05% | -24.96% | +59639.27% |
| Asset Growth | -39.53% | -27.10% | +31.28% | +31.21% | +25.63% |
| Book Value per Share Growth | -70.37% | -70.90% | -67.62% | +22152.84% | +26350.20% |
| Debt Growth | -11.77% | -16.83% | -23.29% | -37.81% | -46.50% |
| R&D Expense Growth | +73.89% | +38.51% | -87.27% | -24.58% | -18.39% |
| SG&A Expenses Growth | +13.90% | -3.28% | +152.84% | +7.74% | +33.92% |